Review article: Coagulation cascade and therapeutics update: Relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants
SUMMARY Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured vessel, in an environment that overwhelmingly favours an anticoagulant state. In the non‐pathological state, the inciting event involves e...
Saved in:
Published in | Nephrology (Carlton, Vic.) Vol. 14; no. 5; pp. 462 - 470 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Melbourne, Australia
Blackwell Publishing Asia
01.08.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | SUMMARY
Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured vessel, in an environment that overwhelmingly favours an anticoagulant state. In the non‐pathological state, the inciting event involves exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, which brings into motion the series of steps which results in amplification of the initial stimulus, culminating in the conversion of fibrinogen to fibrin and clot formation. The precisely synchronized cascade of events is counter‐balanced by a system of anticoagulant mechanisms, which serve to ensure that the haemostatic effect is regulated and does not extend inappropriately. Conversely, in pathological states, these events can escape normal control mechanisms, due to either inherited or acquired defects, which lead to thrombosis. Current anticoagulant therapy, although based on medications that have been in existence for upwards of 80 years, is moving towards targeted therapy for specific coagulation factors and events in the coagulation cascade, based on the current knowledge of the main triggers and key events within the series of reactions that culminates in haemostasis. It remains to be seen whether these newer medications will become first‐line therapies for thrombosis in the coming decade. This review aims to elucidate the main events within the coagulation cascade as it is currently understood to operate in vivo, with a brief discussion focusing on hypercoagulable states, and also a short review of the history of anticoagulants as they relate to this model. |
---|---|
AbstractList | Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured vessel, in an environment that overwhelmingly favours an anticoagulant state. In the non-pathological state, the inciting event involves exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, which brings into motion the series of steps which results in amplification of the initial stimulus, culminating in the conversion of fibrinogen to fibrin and clot formation. The precisely synchronized cascade of events is counter-balanced by a system of anticoagulant mechanisms, which serve to ensure that the haemostatic effect is regulated and does not extend inappropriately. Conversely, in pathological states, these events can escape normal control mechanisms, due to either inherited or acquired defects, which lead to thrombosis. Current anticoagulant therapy, although based on medications that have been in existence for upwards of 80 years, is moving towards targeted therapy for specific coagulation factors and events in the coagulation cascade, based on the current knowledge of the main triggers and key events within the series of reactions that culminates in haemostasis. It remains to be seen whether these newer medications will become first-line therapies for thrombosis in the coming decade. This review aims to elucidate the main events within the coagulation cascade as it is currently understood to operate in vivo, with a brief discussion focusing on hypercoagulable states, and also a short review of the history of anticoagulants as they relate to this model. SUMMARY Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured vessel, in an environment that overwhelmingly favours an anticoagulant state. In the non‐pathological state, the inciting event involves exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, which brings into motion the series of steps which results in amplification of the initial stimulus, culminating in the conversion of fibrinogen to fibrin and clot formation. The precisely synchronized cascade of events is counter‐balanced by a system of anticoagulant mechanisms, which serve to ensure that the haemostatic effect is regulated and does not extend inappropriately. Conversely, in pathological states, these events can escape normal control mechanisms, due to either inherited or acquired defects, which lead to thrombosis. Current anticoagulant therapy, although based on medications that have been in existence for upwards of 80 years, is moving towards targeted therapy for specific coagulation factors and events in the coagulation cascade, based on the current knowledge of the main triggers and key events within the series of reactions that culminates in haemostasis. It remains to be seen whether these newer medications will become first‐line therapies for thrombosis in the coming decade. This review aims to elucidate the main events within the coagulation cascade as it is currently understood to operate in vivo , with a brief discussion focusing on hypercoagulable states, and also a short review of the history of anticoagulants as they relate to this model. SUMMARY Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured vessel, in an environment that overwhelmingly favours an anticoagulant state. In the non‐pathological state, the inciting event involves exposure of circulating factor VII/VIIa to extravascularly expressed tissue factor, which brings into motion the series of steps which results in amplification of the initial stimulus, culminating in the conversion of fibrinogen to fibrin and clot formation. The precisely synchronized cascade of events is counter‐balanced by a system of anticoagulant mechanisms, which serve to ensure that the haemostatic effect is regulated and does not extend inappropriately. Conversely, in pathological states, these events can escape normal control mechanisms, due to either inherited or acquired defects, which lead to thrombosis. Current anticoagulant therapy, although based on medications that have been in existence for upwards of 80 years, is moving towards targeted therapy for specific coagulation factors and events in the coagulation cascade, based on the current knowledge of the main triggers and key events within the series of reactions that culminates in haemostasis. It remains to be seen whether these newer medications will become first‐line therapies for thrombosis in the coming decade. This review aims to elucidate the main events within the coagulation cascade as it is currently understood to operate in vivo, with a brief discussion focusing on hypercoagulable states, and also a short review of the history of anticoagulants as they relate to this model. |
Author | BIRD, ROBERT J ADAMS, REBECCA L C |
Author_xml | – sequence: 1 givenname: REBECCA L C surname: ADAMS fullname: ADAMS, REBECCA L C organization: Pathology Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia – sequence: 2 givenname: ROBERT J surname: BIRD fullname: BIRD, ROBERT J organization: Pathology Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19674315$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkV9v0zAUxS00xP7AV0B-4okEO4ljZxIPqBoFMXXVAPXRcuybNSWNMzvp2s_DF8Vpqu0Vv_hK_p1zrnwu0VlrW0AIUxLTcD5tYpplJKK84HFCSBETShMR71-hi-eHszCnCYlYysQ5uvR-QwjlSU7foHNa5DxLKbtAf-9hV8MTVq6vdQPXeGbVw9CovrYt1sprZQCr1uB-DU51MATM46Ezqg_wPTSwU60G3FvcQrd2trEPhxgvgx-m1_huB-7obyusX5w_Bjtnt6Xt1nVTK39MWNe-t-4woqoNMRPe9v4tel2pxsO7032Ffn-9-TX7Ft3ezb_PvtxGOmNMRJwlRpcmY0RRxoEIwnNVci1UqoxOgArBuSjLJKGQG8JUyQzXphCkolVJWXqFPky-nbOPA_hebmuvoQlLgB28zDkTtDiCYgK1s947qGTn6q1yB0mJHAuSGzn2IMce5FiQPBYk90H6_pQxlFswL8JTIwH4PAFPdQOH_zaWi5vlOAV9NOnDb8L-Wa_cn7B_yplcLeaSzH-sFqtlIX-m_wBH4bPM |
CitedBy_id | crossref_primary_10_1016_j_rpth_2023_102160 crossref_primary_10_1016_j_jep_2023_116562 crossref_primary_10_1128_microbiolspec_PSIB_0004_2018 crossref_primary_10_1002_jat_4202 crossref_primary_10_1074_jbc_M113_493122 crossref_primary_10_1016_j_aanat_2014_06_002 crossref_primary_10_1007_s11239_021_02621_1 crossref_primary_10_3389_fmed_2023_1252417 crossref_primary_10_3390_molecules23112859 crossref_primary_10_1038_s41598_021_01660_1 crossref_primary_10_1002_ajh_24067 crossref_primary_10_1016_j_mporth_2020_03_010 crossref_primary_10_1016_j_arabjc_2017_09_017 crossref_primary_10_1038_s41540_021_00202_9 crossref_primary_10_1017_S0031182020000104 crossref_primary_10_1021_acsptsci_3c00052 crossref_primary_10_1155_2015_369758 crossref_primary_10_1016_j_ijoa_2013_05_008 crossref_primary_10_1039_C6CC08716G crossref_primary_10_1021_acschembio_5b00189 crossref_primary_10_1016_j_bmcl_2023_129241 crossref_primary_10_1007_s00281_011_0290_8 crossref_primary_10_3390_v13030356 crossref_primary_10_1038_s41422_019_0260_6 crossref_primary_10_1016_j_ajpath_2015_10_020 crossref_primary_10_1002_ppap_201300027 crossref_primary_10_1007_s00281_011_0299_z crossref_primary_10_1007_s40290_017_0209_3 crossref_primary_10_1038_srep29387 crossref_primary_10_1021_acs_biochem_3c00066 crossref_primary_10_3923_ijp_2010_142_146 crossref_primary_10_1080_14656566_2024_2364057 crossref_primary_10_1111_j_1440_1797_2010_01298_x crossref_primary_10_3389_fpara_2023_1128299 crossref_primary_10_1517_14728222_2011_553608 crossref_primary_10_3390_pathogens10010043 crossref_primary_10_3390_ijms241612563 crossref_primary_10_1097_JTN_0000000000000256 crossref_primary_10_1039_C5SC01698C crossref_primary_10_1038_cdd_2015_122 crossref_primary_10_1021_acs_jmedchem_8b00173 crossref_primary_10_3810_hp_2012_08_990 crossref_primary_10_1016_j_str_2018_05_018 crossref_primary_10_1016_j_coms_2016_06_002 crossref_primary_10_1080_14656566_2018_1551361 crossref_primary_10_1038_nrneph_2015_177 crossref_primary_10_1021_acsbiomaterials_3c00912 crossref_primary_10_1038_s41467_023_44231_w crossref_primary_10_1177_0310057X1604400601 crossref_primary_10_1016_j_bbrc_2017_10_139 crossref_primary_10_3390_jcs6080226 crossref_primary_10_1016_j_bios_2021_113856 crossref_primary_10_51847_GRccY6BTJ6 crossref_primary_10_1126_scitranslmed_aaf5045 crossref_primary_10_3390_pr3010178 crossref_primary_10_2478_fzm_2021_0005 crossref_primary_10_1016_j_biocon_2020_108696 crossref_primary_10_1177_0897190018775580 crossref_primary_10_1007_s13659_017_0126_x crossref_primary_10_1016_j_imbio_2023_152707 crossref_primary_10_1016_j_mehy_2017_10_021 crossref_primary_10_3390_md20100654 crossref_primary_10_1007_s40262_022_01110_9 crossref_primary_10_3390_molecules29071453 crossref_primary_10_1186_s13054_016_1275_8 crossref_primary_10_1016_j_aan_2014_08_009 crossref_primary_10_1016_j_imbio_2016_06_005 crossref_primary_10_1016_j_ejmech_2016_05_039 crossref_primary_10_1002_rnc_5963 crossref_primary_10_1002_med_21489 crossref_primary_10_1186_s12882_020_01984_6 crossref_primary_10_1016_j_jtbi_2014_07_012 crossref_primary_10_1111_hdi_12241 crossref_primary_10_1097_ALN_0b013e318297c18a crossref_primary_10_3390_jpm12071140 crossref_primary_10_1016_j_disamonth_2018_03_003 crossref_primary_10_1055_s_0043_1774796 crossref_primary_10_1002_jcp_26249 crossref_primary_10_1016_j_thromres_2018_01_021 crossref_primary_10_3747_pdi_2013_00036 crossref_primary_10_1016_j_beha_2022_101349 crossref_primary_10_1002_jcp_26065 crossref_primary_10_1016_j_cgh_2017_06_028 crossref_primary_10_1007_s00281_011_0280_x crossref_primary_10_1016_j_thromres_2012_11_020 crossref_primary_10_3390_medicina56050242 crossref_primary_10_1002_path_4454 crossref_primary_10_1016_j_ijbiomac_2020_08_069 crossref_primary_10_1051_parasite_2022034 crossref_primary_10_1021_acsbiomaterials_1c01437 crossref_primary_10_3390_ani12030361 crossref_primary_10_1115_1_4052460 crossref_primary_10_1089_ten_teb_2014_0188 crossref_primary_10_2165_11207700_000000000_00000 crossref_primary_10_1038_s41598_020_71755_8 crossref_primary_10_1345_aph_1Q119 crossref_primary_10_15446_revfacmed_v64n2_53789 crossref_primary_10_1177_1479164116675488 crossref_primary_10_3389_fneph_2023_1133910 crossref_primary_10_1146_annurev_pathol_012615_044351 crossref_primary_10_3390_ani11030804 crossref_primary_10_1016_S0049_3848_20_30405_9 crossref_primary_10_1016_j_tru_2023_100130 crossref_primary_10_1016_j_bea_2022_100049 crossref_primary_10_1021_acs_macromol_2c02501 |
Cites_doi | 10.1161/01.ATV.0000046238.23903.FC 10.1067/mcp.2002.124522 10.1002/bies.10360 10.1016/0925-4439(94)90086-8 10.1592/phco.20.4.318.34881 10.1161/01.RES.83.3.264 10.1056/NEJM199709043371007 10.1182/blood-2007-01-070631 10.1161/ATVBAHA.107.141911 10.1016/S0140-6736(00)02225-X 10.1024/0369-8394.95.12.455 10.1007/s11239-006-9030-7 10.1378/chest.126.3_suppl.188S 10.1111/j.1365-2141.2007.06548.x 10.1124/jpet.107.121830 10.1016/j.transci.2007.12.007 10.1016/j.jacc.2007.02.065 10.1023/A:1013985911759 10.1097/MOH.0b013e3283063a3e 10.1111/j.1742-4658.2005.04880.x 10.1016/S0140-6736(07)61445-7 10.1157/13113924 10.1093/ndt/gfn029 10.1016/S0021-9258(18)51407-1 10.1074/jbc.M400727200 10.1111/j.1537-2995.2006.00692.x 10.1182/blood.V60.6.1353.1353 10.1097/00005344-200405000-00009 10.1016/j.bcmd.2005.12.034 10.1111/j.1365-2141.2008.07119.x 10.1182/blood-2006-06-030619 10.1161/01.ATV.0000151624.45775.13 10.1182/blood-2007-08-107698 10.1046/j.1538-7836.2003.00361.x 10.1055/s-2007-985753 10.1111/j.1365-2141.2008.07339.x 10.1182/blood.V69.2.381.381 10.7326/0003-4819-138-9-200305060-00007 10.1152/jappl.1994.77.5.2305 10.1056/NEJMoa076016 10.1073/pnas.74.12.5260 10.1016/S0021-9258(18)83213-6 10.1002/ajh.2830160312 10.1111/j.1538-7836.2007.02482.x 10.1182/blood.V95.5.1694.005k24_1694_1702 10.1161/01.ATV.0000193624.28251.83 10.1182/blood-2004-03-1095 10.1016/j.hoc.2006.11.004 10.1126/science.145.3638.1310 10.3109/10409238009105469 10.1038/415175a 10.1074/jbc.M008160200 10.1016/j.blre.2006.09.001 10.1159/000083832 10.1055/s-0038-1657625 10.1016/S0049-3848(08)70020-3 10.1182/blood-2008-01-077909 10.1592/phco.28.9.1084 10.1097/01.moh.0000239708.70792.4f 10.1093/eurheartj/ehl492 10.1038/383073a0 10.1073/pnas.98.4.1823 10.1016/j.beha.2004.03.004 10.1055/s-0038-1642658 |
ContentType | Journal Article |
Copyright | 2009 The Authors. Journal compilation © 2009 Asian Pacific Society of Nephrology |
Copyright_xml | – notice: 2009 The Authors. Journal compilation © 2009 Asian Pacific Society of Nephrology |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1111/j.1440-1797.2009.01128.x |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1797 |
EndPage | 470 |
ExternalDocumentID | 10_1111_j_1440_1797_2009_01128_x 19674315 NEP1128 ark_67375_WNG_0GKWNWP9_S |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1OB 1OC 29M 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABHUG ABJNI ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHEFC AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KMS LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 XVB YFH ZZTAW ~IA ~WT AITYG HGLYW OIG CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4558-752dcbd450a157e08076ab7c8a3adc2e188778bb221e6d05ab5d7cd980f1fb153 |
IEDL.DBID | DR2 |
ISSN | 1320-5358 |
IngestDate | Fri Aug 16 08:48:40 EDT 2024 Fri Aug 23 01:58:09 EDT 2024 Sat Sep 28 07:56:35 EDT 2024 Sat Aug 24 00:57:58 EDT 2024 Wed Jan 17 05:04:36 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4558-752dcbd450a157e08076ab7c8a3adc2e188778bb221e6d05ab5d7cd980f1fb153 |
Notes | ark:/67375/WNG-0GKWNWP9-S ArticleID:NEP1128 istex:C16C77BD9EC0D092EABE97C81D5F90B59E791778 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1797.2009.01128.x |
PMID | 19674315 |
PQID | 67581915 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_67581915 crossref_primary_10_1111_j_1440_1797_2009_01128_x pubmed_primary_19674315 wiley_primary_10_1111_j_1440_1797_2009_01128_x_NEP1128 istex_primary_ark_67375_WNG_0GKWNWP9_S |
PublicationCentury | 2000 |
PublicationDate | 2009-08 August 2009 2009-Aug 2009-08-00 20090801 |
PublicationDateYYYYMMDD | 2009-08-01 |
PublicationDate_xml | – month: 08 year: 2009 text: 2009-08 |
PublicationDecade | 2000 |
PublicationPlace | Melbourne, Australia |
PublicationPlace_xml | – name: Melbourne, Australia – name: Australia |
PublicationTitle | Nephrology (Carlton, Vic.) |
PublicationTitleAlternate | Nephrology (Carlton) |
PublicationYear | 2009 |
Publisher | Blackwell Publishing Asia |
Publisher_xml | – name: Blackwell Publishing Asia |
References | Middeldorp S, Van Hyckama Vleig A. Does thrombophilia testing help in the clinical management of patients? BJH 2008; 143: 321-35. Giuliano RP, Wiviott SD, Stone PH et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: The ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol. 2007; 49: 2398-407. Pérez-Gómez F, Bover R. The new coagulation cascade and its possible influence on the delicate balance between thrombosis and hemorrhage. Rev. Esp. Cardiol. 2007; 60: 1217-19. Osterud B, Rappaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad. Sci. U.S.A. 1977; 74: 5260-64. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008; 28: 1084-97. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29. Orfeo T, Brufatto N, Nesheim ME et al. The factor V activation paradox. J. Biol. Chem. 2004; 279: 19580-91. Bauer KA. Fondaparinux: A new synthetic and selective inhibitor or Factor Xa. Best Pract. Res. Clin. Haematol. 2004; 17: 89-104. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 2003; 12: 17-25. Coiteux I, Mazzolai L Deep vein thrombosis: Epidemiology, risk factors and natural history. Praxis 2006; 95: 455-9. Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67: 3-12. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1687-93. Davie EW, Ratnoff SI. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-12. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol. Haemost. Thromb. 2004; 33: 375-81. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27. Chavin SI. Factor VIII: Structure and function in blood clotting. Am. J. Hematol. 1984; 16: 297-306. Kovacs MJ, Rodger M, Anderson DR et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann. Intern. Med. 2003; 138: 714-19. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood 2007; 21: 157-71. Greer P, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds). Wintrobes Clinical Hematology, 11th, edn. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004. Panes O, Matus V, Sáez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007; 109: 5242-50. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crysallization of the hemorrhagic agent. J. Biol. Chem. 1941; 138: 21-33. Chang J. The hirudin binding site of human a-thrombin. J. Biol. Chem. 1989; 264: 7141-46. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-72. Furie B, Furie C. In vivo thrombus formation. J. Thromb. Haemost. 2007; 5: S12-17. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol. Dis. 2006; 36: 108-17. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microparticles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 206: 1604-11. Dale GL, Friese P, Batar P et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175-9. Spronk HMH, Govers-Riemslag JWP, Ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003; 25: 1220-28. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev. 2007; 21: 157-71. Bungay S. Modelling the effect of amplification pathway factors on thrombin generation: A comparison of hemophilias. Transfus. Apher. Sci. 2008; 38: 41-7. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler. Thromb. Vasc. Biol. 2006; 26: 41-8. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion 2006; 46: 143-52. Pike RN, Buckle AM, Le Bonnie BF, Church FC. Control of the coagulation system by serpins; Getting by with a little help from glycosaminoglycans. FEBS J. 2005; 272: 4842-51. Syzmanski LM, Pate RR, Durstie JL. Effects of maximal exercise and venous occlusion on fibrinolytic activity in physically active and inactive men. J. Appl. Physiol. 1994; 77: 2305-10. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb. Hemost. 1997; 78: 759-64. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: Implications for testing. Semin. Thromb. Hemost. 2007; 33: 573-81. Hoffman M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol. Oncol. Clin. North Am. 2007; 21: 1-11. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 1989; 134: 1087-97. George FD. Microparticles in vascular diseases. Thromb. Res. 2008; 122: S55-9. Bronze GJ. Tissue factor pathway inhibitor. Thromb. Haemost. 1995; 74: 90-93. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1994; 202: 98-9. De Caterina R, Husted S, Wallentin L et al. Anticoagulants in heart disease: Current status and perspectives. Eur. Heart J. 2007; 28: 880-913. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: The Seventh ACP Conference on Antothrombotic and Thrombolytic Therapy. Chest 2004; 126: 1885-2035. Kamali F. Genetic influences on the response to warfarin. Curr. Opin. Hematol. 2006; 13: 357-61. Kalafatis M, Swords NA, Rand MD, Mann KG. Membrane-dependent reaction in blood coagulation: Role of the vitamin K dependent complexes. Biochem. Biophys. Acta. 1994; 1227: 113-29. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th edn. Philadelphia, PA: Lippincott, Williams and Wilkins, 2006. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signalling. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 47-56. Key NS, Geng J, Bach RR. Tissue factor; From Morawitz to microparticles. Trans. Am. Clin. Climatol. Assoc. 2007; 118: 165-73. Weitz JI. Low molecular weight heparins. N. Engl. J. Med. 1997; 337: 688-98. Hoffman R, Benz E, Shattil SJ, Furie Bruce, Cohen H (eds). Hematology: Basic Principles and Practice, 4th edn. Philadelphia, PA: Elsevier, 2005. Daniel L, Dou L, Berland Y, Lesavre P, Mecarelli-Halbwachs L, Dignat-George F. Circulating microparticles in renal diseases. Nephrol. Dial. Transplant. 2008; 23: 2129-32. Suttie JW. Mechanism of action of vitamin K: Synthesis of gamma-carboxyglutamic acid. CRC Crit. Rev. Biochem. 1980; 8: 191-223. Lassen MR, Ageno W, Borris LC et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008; 358: 2776-86. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr. Opin. Hematol. 2008; 15: 522-8. Redecha P, Tilley R, Tencati M et al. Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 2007; 110: 2423-31. Mackman N, Sawley MS, Keeton MR, Loskutoff DJ. Murine tissue factor gene espression in vivo: Tissue and cell specificity and regulation by lipopolysaccharide. Am. J. Pathol. 1993; 143: 76-84. Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad. Sci. U.S.A. 2001; 98: 1823-8. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. BJH 2008; 141: 757-63. Kempton CL, Hoffman M, Roberts HR et al. Platelet heterogeneity: Variation in coagulation complexes on platelet subpopulations. Arterioscler. Thromb. Vasc. Biol. 205: 861-6. Corrál J, González-Conejero R, Hernandez-Espinosa D, Vicente V. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br. J. Haematol. 2007; 137: 99-108. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7. Biloduae ML, Hamm HE. Regulation of protease-activated reveptor (PAR)1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions. J. Pharmacol. Exp. Ther. 2007; 322: 778-88. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56. Dahlbäck B. Blood coagulation. Lancet 2000; 355: 1627-32. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR-1 on intact platelets. J. Biol. Chem. 2001; 276: 4692-8. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender. Clin. Pharmacol. Ther. 2002; 71: 433-9. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-58. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-32. Viles-Gonzalez JF, Annand SX, Zafar MU, Fuster V, Badimon JJ. Tissue factor coagulation pathway: A new therapeutic target in atherothrombosis. J. Cardiovasc. Pharmacol. 2004; 43: 669-76. Egorina EM, Sovershaev MA, Olsen JO, Østerud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: Evidence for a direct transfer. Blood 2008; 111: 1208-16. Romanic AM, Arleth AJ, Willette RN, Ohlstein EH. Factor XIIIa cross-links lipoprotein(a) with fib 1941; 138 1995; 74 2004; 126 2008; 38 2000; 85 2006; 36 1998; 83 1996; 383 2007; 109 2003; 95 2007; 33 2008; 143 2008; 141 2005; 25 2003; 12 2007; 28 2004; 33 2007; 137 2007; 370 1982; 60 1984; 16 2006; 22 1989; 264 2006; 26 2008; 28 1964; 145 1994; 77 2008; 23 1977; 74 2007; 60 2008; 358 2007; 5 2003; 1 205 2008; 112 2007; 21 2008; 111 2007; 27 2001; 98 2004; 43 2007; 322 1997; 337 2005; 272 2006; 95 2003; 138 2000; 355 1989; 134 2006; 13 2000; 20 2008; 15 2002; 415 2006 2005 1994; 1227 2004 2008; 122 1993; 143 2001; 276 1987; 69 2007; 118 1994; 202 2004; 279 2006; 46 2004; 17 2002; 67 2007; 110 1997; 78 2005; 206 2003; 25 1980; 8 2002; 71 2007; 49 Hoffman R (e_1_2_9_2_2) 2005 e_1_2_9_52_2 e_1_2_9_71_2 Grignani G (e_1_2_9_23_2) 2000; 85 e_1_2_9_33_2 e_1_2_9_56_2 e_1_2_9_77_2 e_1_2_9_12_2 e_1_2_9_31_2 e_1_2_9_54_2 e_1_2_9_75_2 Drake TA (e_1_2_9_22_2) 1989; 134 Mackman N (e_1_2_9_21_2) 1993; 143 Chang J (e_1_2_9_73_2) 1989; 264 e_1_2_9_14_2 e_1_2_9_37_2 e_1_2_9_16_2 e_1_2_9_35_2 e_1_2_9_58_2 MacFarlane RG (e_1_2_9_4_2) 1994; 202 e_1_2_9_39_2 e_1_2_9_41_2 e_1_2_9_60_2 Colman RW (e_1_2_9_69_2) 2006 Marlar RA (e_1_2_9_10_2) 1982; 60 e_1_2_9_66_2 Greer P (e_1_2_9_17_2) 2004 e_1_2_9_43_2 e_1_2_9_64_2 e_1_2_9_6_2 Bronze GJ (e_1_2_9_53_2) 1995; 74 Key NS (e_1_2_9_18_2) 2007; 118 Campbell HA (e_1_2_9_62_2) 1941; 138 e_1_2_9_8_2 e_1_2_9_24_2 e_1_2_9_49_2 e_1_2_9_26_2 Alberio L (e_1_2_9_45_2) 2003; 95 e_1_2_9_68_2 e_1_2_9_28_2 Syzmanski LM (e_1_2_9_51_2) 1994; 77 Semeraro N (e_1_2_9_20_2) 1997; 78 e_1_2_9_74_2 e_1_2_9_30_2 Kempton CL (e_1_2_9_47_2); 205 e_1_2_9_72_2 e_1_2_9_78_2 e_1_2_9_34_2 e_1_2_9_55_2 e_1_2_9_76_2 e_1_2_9_11_2 e_1_2_9_32_2 e_1_2_9_70_2 e_1_2_9_13_2 e_1_2_9_38_2 e_1_2_9_59_2 e_1_2_9_15_2 e_1_2_9_57_2 e_1_2_9_19_2 e_1_2_9_40_2 e_1_2_9_63_2 e_1_2_9_61_2 e_1_2_9_44_2 e_1_2_9_67_2 Mackmann N (e_1_2_9_36_2) 1993; 143 e_1_2_9_42_2 e_1_2_9_65_2 e_1_2_9_7_2 e_1_2_9_5_2 e_1_2_9_3_2 Greer P (e_1_2_9_50_2) 2004 e_1_2_9_9_2 e_1_2_9_25_2 e_1_2_9_48_2 e_1_2_9_27_2 e_1_2_9_46_2 e_1_2_9_29_2 |
References_xml | – volume: 95 start-page: 455 year: 2006 end-page: 9 article-title: Deep vein thrombosis: Epidemiology, risk factors and natural history publication-title: Praxis – volume: 415 start-page: 175 year: 2002 end-page: 9 article-title: Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface publication-title: Nature – year: 2005 – volume: 143 start-page: 76 year: 1993 end-page: 84 article-title: Murine tissue factor gene espression : Tissue and cell specificity and regulation by lipopolysaccharide publication-title: Am. J. Pathol. – volume: 206 start-page: 1604 year: 2005 end-page: 11 article-title: Tissue‐factor‐bearing microparticles arise from lipid rafts and fuse with activated platelets to initiate coagulation publication-title: Blood – volume: 137 start-page: 99 year: 2007 end-page: 108 article-title: Protein Z/Z‐dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis publication-title: Br. J. Haematol. – volume: 205 start-page: 861 end-page: 6 article-title: Platelet heterogeneity: Variation in coagulation complexes on platelet subpopulations publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 138 start-page: 714 year: 2003 end-page: 19 article-title: Comparison of 10‐mg and 5‐mg warfarin initiation nomograms together with low‐molecular‐weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double‐blind, controlled trial publication-title: Ann. Intern. Med. – volume: 49 start-page: 2398 year: 2007 end-page: 407 article-title: Recombinant nematode anticoagulant protein c2 in patients with non‐ST‐segment elevation acute coronary syndrome: The ANTHEM‐TIMI‐32 trial publication-title: J. Am. Coll. Cardiol. – volume: 77 start-page: 2305 year: 1994 end-page: 10 article-title: Effects of maximal exercise and venous occlusion on fibrinolytic activity in physically active and inactive men publication-title: J. Appl. Physiol. – volume: 358 start-page: 2776 year: 2008 end-page: 86 article-title: RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty publication-title: N. Engl. J. Med. – volume: 36 start-page: 108 year: 2006 end-page: 17 article-title: Models of blood coagulation publication-title: Blood Cells Mol. Dis. – volume: 20 start-page: 318 year: 2000 end-page: 29 article-title: The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction publication-title: Pharmacotherapy – volume: 15 start-page: 522 year: 2008 end-page: 8 article-title: Tissue factor in cancer publication-title: Curr. Opin. Hematol. – volume: 383 start-page: 73 year: 1996 end-page: 5 article-title: Role of tissue factor in embryonic blood vessel development publication-title: Nature – volume: 276 start-page: 4692 year: 2001 end-page: 8 article-title: Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR‐1 on intact platelets publication-title: J. Biol. Chem. – volume: 118 start-page: 165 year: 2007 end-page: 73 article-title: Tissue factor; From Morawitz to microparticles publication-title: Trans. Am. Clin. Climatol. Assoc. – volume: 143 start-page: 321 year: 2008 end-page: 35 article-title: Does thrombophilia testing help in the clinical management of patients? publication-title: BJH – volume: 12 start-page: 17 year: 2003 end-page: 25 article-title: The dynamics of thrombin formation publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 98 start-page: 1823 year: 2001 end-page: 8 article-title: A thrombin receptor function for platelet glycoprotein Ib‐IX unmasked by cleavage of glycoprotein V publication-title: Proc Natl Acad. Sci. U.S.A. – volume: 38 start-page: 41 year: 2008 end-page: 7 article-title: Modelling the effect of amplification pathway factors on thrombin generation: A comparison of hemophilias publication-title: Transfus. Apher. Sci. – volume: 23 start-page: 2129 year: 2008 end-page: 32 article-title: Circulating microparticles in renal diseases publication-title: Nephrol. Dial. Transplant. – volume: 67 start-page: 3 year: 2002 end-page: 12 article-title: Blood coagulation publication-title: Biochemistry – volume: 145 start-page: 1310 year: 1964 end-page: 12 article-title: Waterfall sequence for intrinsic blood clotting publication-title: Science – volume: 1 start-page: 1920 year: 2003 end-page: 26 article-title: Pro‐ and non‐coagulant forms of non‐cell bound tissue factor publication-title: J Thromb Haemost. – volume: 21 start-page: 1 year: 2007 end-page: 11 article-title: Coagulation 2006: A modern view of hemostasis publication-title: Hematol. Oncol. Clin. North Am. – year: 2004 – volume: 112 start-page: 19 year: 2008 end-page: 27 article-title: Advances in understanding pathogenic mechanisms of thrombophilic disorders publication-title: Blood – volume: 69 start-page: 381 year: 1987 end-page: 7 article-title: Plasminogen activator inhibitors publication-title: Blood – volume: 279 start-page: 19580 year: 2004 end-page: 91 article-title: The factor V activation paradox publication-title: J. Biol. Chem. – volume: 143 start-page: 76 year: 1993 end-page: 84 article-title: Murine tissue factor gene expression : Tissue and cell specificity and regulation by lipopolysaccharide publication-title: Am. J. Pathol. – volume: 109 start-page: 5242 year: 2007 end-page: 50 article-title: Human platelets synthesize and express functional tissue factor publication-title: Blood – volume: 13 start-page: 357 year: 2006 end-page: 61 article-title: Genetic influences on the response to warfarin publication-title: Curr. Opin. Hematol. – volume: 141 start-page: 757 year: 2008 end-page: 63 article-title: The story of the discovery of heparin and warfarin publication-title: BJH – volume: 134 start-page: 1087 year: 1989 end-page: 97 article-title: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis publication-title: Am. J. Pathol. – volume: 21 start-page: 157 year: 2007 end-page: 71 article-title: Circulating microparticles publication-title: Blood – volume: 126 start-page: 1885 year: 2004 end-page: 2035 article-title: Heparin and low‐molecular weight heparin: The Seventh ACP Conference on Antothrombotic and Thrombolytic Therapy publication-title: Chest – volume: 28 start-page: 880 year: 2007 end-page: 913 article-title: Anticoagulants in heart disease: Current status and perspectives publication-title: Eur. Heart J. – volume: 46 start-page: 143 year: 2006 end-page: 52 article-title: The how and why of exocytic vesicles publication-title: Transfusion – volume: 16 start-page: 297 year: 1984 end-page: 306 article-title: Factor VIII: Structure and function in blood clotting publication-title: Am. J. Hematol. – volume: 95 start-page: 1694 year: 2003 end-page: 702 article-title: Surface expression and functional characterization of alpha‐granule factor V in human platelets: Effects of ionophore A123187, thrombin, collagen, and convulxin publication-title: Blood – volume: 71 start-page: 433 year: 2002 end-page: 9 article-title: Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender publication-title: Clin. Pharmacol. Ther. – volume: 111 start-page: 1208 year: 2008 end-page: 16 article-title: Granulocytes do not express but acquire monocyte‐derived tissue factor in whole blood: Evidence for a direct transfer publication-title: Blood – volume: 28 start-page: 1084 year: 2008 end-page: 97 article-title: Warfarin pharmacogenetics publication-title: Pharmacotherapy – volume: 122 start-page: S55 year: 2008 end-page: 9 article-title: Microparticles in vascular diseases publication-title: Thromb. Res. – volume: 138 start-page: 21 year: 1941 end-page: 33 article-title: Studies on the hemorrhagic sweet clover disease. IV. The isolation and crysallization of the hemorrhagic agent publication-title: J. Biol. Chem. – volume: 355 start-page: 1627 year: 2000 end-page: 32 article-title: Blood coagulation publication-title: Lancet – volume: 5 start-page: S12 year: 2007 end-page: 17 article-title: In vivo thrombus formation publication-title: J. Thromb. Haemost. – volume: 74 start-page: 90 year: 1995 end-page: 93 article-title: Tissue factor pathway inhibitor publication-title: Thromb. Haemost. – volume: 27 start-page: 1687 year: 2007 end-page: 93 article-title: Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 8 start-page: 191 year: 1980 end-page: 223 article-title: Mechanism of action of vitamin K: Synthesis of gamma‐carboxyglutamic acid publication-title: CRC Crit. Rev. Biochem. – volume: 25 start-page: 47 year: 2005 end-page: 56 article-title: Tissue factor‐factor VIIa signalling publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 60 start-page: 1353 year: 1982 end-page: 58 article-title: An alternative extrinsic pathway of human blood coagulation publication-title: Blood – volume: 337 start-page: 688 year: 1997 end-page: 98 article-title: Low molecular weight heparins publication-title: N. Engl. J. Med. – volume: 25 start-page: 1220 year: 2003 end-page: 28 article-title: The blood coagulation system as a molecular machine publication-title: Bioessays – volume: 264 start-page: 7141 year: 1989 end-page: 46 article-title: The hirudin binding site of human a‐thrombin publication-title: J. Biol. Chem. – volume: 33 start-page: 375 year: 2004 end-page: 81 article-title: Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis publication-title: Pathophysiol. Haemost. Thromb. – volume: 202 start-page: 98 year: 1994 end-page: 9 article-title: An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier publication-title: Nature – volume: 85 start-page: 967 year: 2000 end-page: 72 article-title: Cytokines and hemostasis publication-title: Haematologica – volume: 370 start-page: 949 year: 2007 end-page: 56 article-title: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double‐blind, non‐inferiority trial publication-title: Lancet – volume: 21 start-page: 157 year: 2007 end-page: 71 article-title: Circulating microparticles publication-title: Blood Rev. – volume: 43 start-page: 669 year: 2004 end-page: 76 article-title: Tissue factor coagulation pathway: A new therapeutic target in atherothrombosis publication-title: J. Cardiovasc. Pharmacol. – volume: 110 start-page: 2423 year: 2007 end-page: 31 article-title: Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody–induced fetal injury publication-title: Blood – volume: 22 start-page: 191 year: 2006 end-page: 7 – year: 2006 – volume: 33 start-page: 573 year: 2007 end-page: 81 article-title: Thrombophilia and venous thromboembolism: Implications for testing publication-title: Semin. Thromb. Hemost. – volume: 272 start-page: 4842 year: 2005 end-page: 51 article-title: Control of the coagulation system by serpins; Getting by with a little help from glycosaminoglycans publication-title: FEBS J. – volume: 17 start-page: 89 year: 2004 end-page: 104 article-title: Fondaparinux: A new synthetic and selective inhibitor or Factor Xa publication-title: Best Pract. Res. Clin. Haematol. – volume: 1227 start-page: 113 year: 1994 end-page: 29 article-title: Membrane‐dependent reaction in blood coagulation: Role of the vitamin K dependent complexes publication-title: Biochem. Biophys. Acta. – volume: 26 start-page: 41 year: 2006 end-page: 8 article-title: What does it take to make the perfect clot? publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 78 start-page: 759 year: 1997 end-page: 64 article-title: Tissue factor in health and disease publication-title: Thromb. Hemost. – volume: 322 start-page: 778 year: 2007 end-page: 88 article-title: Regulation of protease‐activated reveptor (PAR)1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions publication-title: J. Pharmacol. Exp. Ther. – volume: 83 start-page: 264 year: 1998 end-page: 9 article-title: Factor XIIIa cross‐links lipoprotein(a) with fibrinogen and is present in human atherlsclerotic lesions publication-title: Circ. Res. – volume: 60 start-page: 1217 year: 2007 end-page: 19 article-title: The new coagulation cascade and its possible influence on the delicate balance between thrombosis and hemorrhage publication-title: Rev. Esp. Cardiol. – volume: 74 start-page: 5260 year: 1977 end-page: 64 article-title: Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation publication-title: Proc Natl Acad. Sci. U.S.A. – ident: e_1_2_9_40_2 doi: 10.1161/01.ATV.0000046238.23903.FC – volume: 143 start-page: 76 year: 1993 ident: e_1_2_9_21_2 article-title: Murine tissue factor gene espression in vivo: Tissue and cell specificity and regulation by lipopolysaccharide publication-title: Am. J. Pathol. contributor: fullname: Mackman N – ident: e_1_2_9_74_2 doi: 10.1067/mcp.2002.124522 – volume: 202 start-page: 98 year: 1994 ident: e_1_2_9_4_2 article-title: An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier publication-title: Nature contributor: fullname: MacFarlane RG – volume: 205 start-page: 861 ident: e_1_2_9_47_2 article-title: Platelet heterogeneity: Variation in coagulation complexes on platelet subpopulations publication-title: Arterioscler. Thromb. Vasc. Biol. contributor: fullname: Kempton CL – ident: e_1_2_9_6_2 doi: 10.1002/bies.10360 – volume: 134 start-page: 1087 year: 1989 ident: e_1_2_9_22_2 article-title: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis publication-title: Am. J. Pathol. contributor: fullname: Drake TA – ident: e_1_2_9_11_2 doi: 10.1016/0925-4439(94)90086-8 – ident: e_1_2_9_75_2 doi: 10.1592/phco.20.4.318.34881 – ident: e_1_2_9_49_2 doi: 10.1161/01.RES.83.3.264 – ident: e_1_2_9_70_2 doi: 10.1056/NEJM199709043371007 – ident: e_1_2_9_26_2 doi: 10.1182/blood-2007-01-070631 – ident: e_1_2_9_12_2 doi: 10.1161/ATVBAHA.107.141911 – ident: e_1_2_9_54_2 doi: 10.1016/S0140-6736(00)02225-X – ident: e_1_2_9_57_2 doi: 10.1024/0369-8394.95.12.455 – ident: e_1_2_9_63_2 doi: 10.1007/s11239-006-9030-7 – ident: e_1_2_9_71_2 doi: 10.1378/chest.126.3_suppl.188S – ident: e_1_2_9_56_2 doi: 10.1111/j.1365-2141.2007.06548.x – volume: 118 start-page: 165 year: 2007 ident: e_1_2_9_18_2 article-title: Tissue factor; From Morawitz to microparticles publication-title: Trans. Am. Clin. Climatol. Assoc. contributor: fullname: Key NS – volume-title: Hemostasis and Thrombosis: Basic Principles and Clinical Practice year: 2006 ident: e_1_2_9_69_2 contributor: fullname: Colman RW – ident: e_1_2_9_43_2 doi: 10.1124/jpet.107.121830 – ident: e_1_2_9_8_2 doi: 10.1016/j.transci.2007.12.007 – ident: e_1_2_9_78_2 doi: 10.1016/j.jacc.2007.02.065 – ident: e_1_2_9_16_2 doi: 10.1023/A:1013985911759 – ident: e_1_2_9_33_2 doi: 10.1097/MOH.0b013e3283063a3e – ident: e_1_2_9_55_2 doi: 10.1111/j.1742-4658.2005.04880.x – ident: e_1_2_9_76_2 doi: 10.1016/S0140-6736(07)61445-7 – ident: e_1_2_9_9_2 doi: 10.1157/13113924 – ident: e_1_2_9_31_2 doi: 10.1093/ndt/gfn029 – volume: 138 start-page: 21 year: 1941 ident: e_1_2_9_62_2 article-title: Studies on the hemorrhagic sweet clover disease. IV. The isolation and crysallization of the hemorrhagic agent publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)51407-1 contributor: fullname: Campbell HA – ident: e_1_2_9_39_2 doi: 10.1074/jbc.M400727200 – ident: e_1_2_9_3_2 doi: 10.1016/S0140-6736(00)02225-X – ident: e_1_2_9_29_2 doi: 10.1111/j.1537-2995.2006.00692.x – volume: 60 start-page: 1353 year: 1982 ident: e_1_2_9_10_2 article-title: An alternative extrinsic pathway of human blood coagulation publication-title: Blood doi: 10.1182/blood.V60.6.1353.1353 contributor: fullname: Marlar RA – ident: e_1_2_9_34_2 doi: 10.1097/00005344-200405000-00009 – ident: e_1_2_9_38_2 doi: 10.1016/j.bcmd.2005.12.034 – volume: 143 start-page: 76 year: 1993 ident: e_1_2_9_36_2 article-title: Murine tissue factor gene expression in vivo: Tissue and cell specificity and regulation by lipopolysaccharide publication-title: Am. J. Pathol. contributor: fullname: Mackmann N – ident: e_1_2_9_61_2 doi: 10.1111/j.1365-2141.2008.07119.x – ident: e_1_2_9_24_2 doi: 10.1182/blood-2006-06-030619 – volume-title: Wintrobes Clinical Hematology year: 2004 ident: e_1_2_9_50_2 contributor: fullname: Greer P – ident: e_1_2_9_19_2 doi: 10.1161/01.ATV.0000151624.45775.13 – ident: e_1_2_9_25_2 doi: 10.1182/blood-2007-08-107698 – ident: e_1_2_9_27_2 doi: 10.1046/j.1538-7836.2003.00361.x – ident: e_1_2_9_59_2 doi: 10.1055/s-2007-985753 – ident: e_1_2_9_60_2 doi: 10.1111/j.1365-2141.2008.07339.x – ident: e_1_2_9_52_2 doi: 10.1182/blood.V69.2.381.381 – ident: e_1_2_9_67_2 doi: 10.7326/0003-4819-138-9-200305060-00007 – volume: 77 start-page: 2305 year: 1994 ident: e_1_2_9_51_2 article-title: Effects of maximal exercise and venous occlusion on fibrinolytic activity in physically active and inactive men publication-title: J. Appl. Physiol. doi: 10.1152/jappl.1994.77.5.2305 contributor: fullname: Syzmanski LM – ident: e_1_2_9_77_2 doi: 10.1056/NEJMoa076016 – ident: e_1_2_9_37_2 doi: 10.1073/pnas.74.12.5260 – volume: 264 start-page: 7141 year: 1989 ident: e_1_2_9_73_2 article-title: The hirudin binding site of human a‐thrombin publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)83213-6 contributor: fullname: Chang J – ident: e_1_2_9_7_2 doi: 10.1002/ajh.2830160312 – ident: e_1_2_9_15_2 doi: 10.1111/j.1538-7836.2007.02482.x – volume: 95 start-page: 1694 year: 2003 ident: e_1_2_9_45_2 article-title: Surface expression and functional characterization of alpha‐granule factor V in human platelets: Effects of ionophore A123187, thrombin, collagen, and convulxin publication-title: Blood doi: 10.1182/blood.V95.5.1694.005k24_1694_1702 contributor: fullname: Alberio L – volume: 85 start-page: 967 year: 2000 ident: e_1_2_9_23_2 article-title: Cytokines and hemostasis publication-title: Haematologica contributor: fullname: Grignani G – ident: e_1_2_9_13_2 doi: 10.1161/01.ATV.0000193624.28251.83 – ident: e_1_2_9_32_2 doi: 10.1182/blood-2004-03-1095 – ident: e_1_2_9_14_2 doi: 10.1016/j.hoc.2006.11.004 – volume-title: Wintrobes Clinical Hematology year: 2004 ident: e_1_2_9_17_2 contributor: fullname: Greer P – ident: e_1_2_9_5_2 doi: 10.1126/science.145.3638.1310 – ident: e_1_2_9_64_2 doi: 10.3109/10409238009105469 – volume-title: Hematology: Basic Principles and Practice year: 2005 ident: e_1_2_9_2_2 contributor: fullname: Hoffman R – ident: e_1_2_9_46_2 doi: 10.1038/415175a – ident: e_1_2_9_42_2 doi: 10.1074/jbc.M008160200 – ident: e_1_2_9_28_2 doi: 10.1016/j.blre.2006.09.001 – ident: e_1_2_9_48_2 doi: 10.1159/000083832 – volume: 78 start-page: 759 year: 1997 ident: e_1_2_9_20_2 article-title: Tissue factor in health and disease publication-title: Thromb. Hemost. doi: 10.1055/s-0038-1657625 contributor: fullname: Semeraro N – ident: e_1_2_9_30_2 doi: 10.1016/S0049-3848(08)70020-3 – ident: e_1_2_9_58_2 doi: 10.1182/blood-2008-01-077909 – ident: e_1_2_9_66_2 doi: 10.1592/phco.28.9.1084 – ident: e_1_2_9_65_2 doi: 10.1097/01.moh.0000239708.70792.4f – ident: e_1_2_9_68_2 doi: 10.1093/eurheartj/ehl492 – ident: e_1_2_9_44_2 doi: 10.1016/j.blre.2006.09.001 – ident: e_1_2_9_35_2 doi: 10.1038/383073a0 – ident: e_1_2_9_41_2 doi: 10.1073/pnas.98.4.1823 – ident: e_1_2_9_72_2 doi: 10.1016/j.beha.2004.03.004 – volume: 74 start-page: 90 year: 1995 ident: e_1_2_9_53_2 article-title: Tissue factor pathway inhibitor publication-title: Thromb. Haemost. doi: 10.1055/s-0038-1642658 contributor: fullname: Bronze GJ |
SSID | ssj0017261 |
Score | 2.2871213 |
SecondaryResourceType | review_article |
Snippet | SUMMARY
Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an... Coagulation involves the regulated sequence of proteolytic activation of a series of zymogens to achieve appropriate and timely haemostasis in an injured... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 462 |
SubjectTerms | Animals anticoagulants Anticoagulants - therapeutic use Blood Coagulation Fibrin - metabolism Fibrinolysis haemostasis Hemostasis Humans Thrombin - biosynthesis Thrombophilia - drug therapy thromboplastin (tissue factor) thrombosis |
Title | Review article: Coagulation cascade and therapeutics update: Relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants |
URI | https://api.istex.fr/ark:/67375/WNG-0GKWNWP9-S/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1797.2009.01128.x https://www.ncbi.nlm.nih.gov/pubmed/19674315 https://search.proquest.com/docview/67581915 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9NAFH5CrYS4sC9hKXNAnHDkSTyecW5taVqBGqJCld5GsxmhCDuqHVT4O_xR3rOdtKl6QIibJc_iGX9vm7cMwBsjghoqmUdOypQMlDyyzqOVoiQJ3CQNkhKFjyfp0Wny4UycdfFPlAvT1odYH7gRZTT8mgjc2OoakZNfUmayKzuJqoPqkz5JdfVIPzpZV5JCMZ3yVcKwGAq1GdRz40AbkmqbNv3iJjV0U6ttxNL4HsxXC2qjUeb9ZW377te1Wo__Z8X34W6nvbLdFm4P4FYoHsLt484__wh-t64G1uFxxPZL87W7IIw5U1EwPjOFZ1fSviq2XNCxw4idUK47oZDVJSsCwqw58--zKY7H-Ih9-kGcDccvc-YuR37H6LKH77Zc0OmQqZoZ2kLKP6kpgudb17yoq8dwOj74sn8UdddARC4RQkVSDLyzPhGx4UIGVHFlaqx0ygyNd4PAkU9KZe1gwEPqY2Gs8NL5TMU5zy1y9CewVZRFeAZMOOuQzwTJuU8SJ6wXNnbYbZjnKBVUD_jql-tFW-1DX7WSEnzG3ae7OzPd7L6-6MHbBhvrDuZ8TtFyUujZ5FDHhx9nk9k005978HoFHo00TI4ZU4RyWWky2tBuFj142mLqcvKMkkToTdog46-_Sk8OpvT0_F87voA7reOMYh1fwlZ9vgyvUP-q7Q5s7-693xvvNBT2B5ogJM8 |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JT9tAFB5VILW9tKV0SReYA-JUR57E4xnnhiiQFmIiCgq30WyuKlo7wk5F-Tv9o33PdgJBHKqqN0vxjOPx9_aNkC3NvexLkQVWiBgNlCww1oGVIgUK3Cj2AguFR2k8PIs-n_PzdhwQ1sI0_SEWDjekjJpfI4GjQ_oOlWNgUiSi7TsJuoPsgkK5CtTPkUo_nix6SYGgjtm8ZJj3uVxO67l3pyVZtYrHfnWfIrqs19aCaf8p-T5_pSYf5aI7q0zXXt_p9vif3vkZedIqsHSnQdwaeeDz5-ThqA3Rr5PfTbSBtpAc0N1Cf21nhFGrS8zHpzp39FblV0lnU_Q8DOgJlrsjEGlV0NwD0mq3f5eOYT_KBvT4JzI32L_IqL3Z-QPFeQ8_TDFFB5Eu6yc0vZR_4a2An2_t7XlVviBn-3unu8OgnQQR2IhzGQjec9a4iIeaceFByxWxNsJK3dfO9jwDVimkMb0e87ELuTbcCesSGWYsM8DUX5KVvMj9a0K5NRZYjReMuSiy3DhuQgvL-lkGgkF2CJt_czVtGn6o24ZSBNdw-ji-M1H16aurDtmuwbFYoC8vMGFOcDVJD1R4cDhJJ-NEfemQzTl6FJAxxmZ07otZqdBuA9OZd8irBlQ3D0-wTgR_iWto_PW_UuneGK_e_OvCTfJoeDo6Ukef0sO35HETR8PUx3dkpbqc-fegjlVmoyazP7ZhJ30 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZQK1Vc2JcpS31AnMgoTuLYmRtqOy2UhlGhmt4sb0Fo1GTUZFDh7_BHeS_JTDtVDwhxixQvsfO9zW8xIW809zKWogisECkaKEVgrAMrRQoUuEnqBSYKH-fp4Wny8Yyf9fFPmAvT1YdYHbghZbT8Ggl87oobRI5-SZGJvuwkqA5yCPrkZpLGERpieyerUlIgp1O2zBjmMZfrUT23jrQmqjZx1y9v00PX1dpWLo3vk9lyRV04ymy4aMzQ_rpR7PH_LPkBuderr_R9h7eH5I4vH5Gt495B_5j87nwNtAfkiO5W-lt_Qxi1usZofKpLR6_lfdV0McdzhxE9wWR3hCFtKlp6wFl76D-kExiPshH9_ANZG4xfFdRejfyO4m0P56aa4_GQrtsZukrKP7EpoOd737xs6ifkdLz_dfcw6O-BCGzCuQwEj5w1LuGhZlx40HFFqo2wUsfa2cgzYJRCGhNFzKcu5NpwJ6zLZFiwwgBLf0o2yqr0zwnl1lhgNF4w5pLEcuO4CS10i4sCxIIcELb85WrelftQ182kBJ5h9_Hyzky1u68uB-Rti41VB30xw3A5wdU0P1DhwdE0n04y9WVAdpbgUUDE6JnRpa8WtUKrDQxnPiDPOkxdTZ5hlgi-SVtk_PVXqXx_gk_b_9pxh2xN9sbq04f86AW52znRMO7xJdloLhb-FehijXndEtkfFtYmLA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Review+article%3A+Coagulation+cascade+and+therapeutics+update%3A+relevance+to+nephrology.+Part+1%3A+Overview+of+coagulation%2C+thrombophilias+and+history+of+anticoagulants&rft.jtitle=Nephrology+%28Carlton%2C+Vic.%29&rft.au=Adams%2C+Rebecca+L+C&rft.au=Bird%2C+Robert+J&rft.date=2009-08-01&rft.eissn=1440-1797&rft.volume=14&rft.issue=5&rft.spage=462&rft.epage=470&rft_id=info:doi/10.1111%2Fj.1440-1797.2009.01128.x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1320-5358&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1320-5358&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1320-5358&client=summon |